国际眼科纵览
國際眼科縱覽
국제안과종람
OREIGN MEDICAL SCIENCES
2012年
2期
133-137
,共5页
早产儿视网膜病变%血管内皮细胞生长因子%新生血管形成
早產兒視網膜病變%血管內皮細胞生長因子%新生血管形成
조산인시망막병변%혈관내피세포생장인자%신생혈관형성
retinopathy of prematurity%vascular endothelial growth factor%neovascularization
血管内皮细胞生长因子(VEGF)在早产儿视网膜病变(ROP)的发生过程中发挥重要作用.在ROP的新生血管增生阶段,应用抗VEGF类药物抑制VEGF可以阻断视网膜血管的异常增生.本文就抗VEGF类药物贝伐单抗(Avastin)单纯玻璃体内注射、玻璃体内注射联合视网膜光凝或玻璃体切除手术等不同方式治疗ROP的临床研究进行回顾,并就贝伐单抗治疗ROP的安全性评价进行汇总.
血管內皮細胞生長因子(VEGF)在早產兒視網膜病變(ROP)的髮生過程中髮揮重要作用.在ROP的新生血管增生階段,應用抗VEGF類藥物抑製VEGF可以阻斷視網膜血管的異常增生.本文就抗VEGF類藥物貝伐單抗(Avastin)單純玻璃體內註射、玻璃體內註射聯閤視網膜光凝或玻璃體切除手術等不同方式治療ROP的臨床研究進行迴顧,併就貝伐單抗治療ROP的安全性評價進行彙總.
혈관내피세포생장인자(VEGF)재조산인시망막병변(ROP)적발생과정중발휘중요작용.재ROP적신생혈관증생계단,응용항VEGF류약물억제VEGF가이조단시망막혈관적이상증생.본문취항VEGF류약물패벌단항(Avastin)단순파리체내주사、파리체내주사연합시망막광응혹파리체절제수술등불동방식치료ROP적림상연구진행회고,병취패벌단항치료ROP적안전성평개진행회총.
Vascular endothelial growth factor (VEGF) plays an important role in the development of retinopathy of prematurity (ROP).Inhibition of VEGF expression with anti-VEGF drugs in the neovascular phase of ROP might prevent destructive neovascularization in ROP.Clinical studies of application of bevacizumab (Avastin) in treatment of ROP in different ways which include intravitreal injection,intravitreal injection combined with retinal photocoagulation or vitrectomy were reviewed in this article.Safety of intravitreal injection of bevacizumab for treatment of ROP was also reviewed.
